Alector, Inc.

Alector, Inc. has entered into a Sales Agreement with TD Securities (USA) LLC to establish an at-the-market equity offering program. Under this agreement, Alector may sell up to $125,000,000 of its common stock from time to time. The net proceeds from any sales are intended for general corporate purposes, including research, development, manufacturing of product candidates, working capital, and potential strategic transactions.

Alector, Inc. reported a significant reduction in its net loss for the first quarter of 2026, narrowing to $(22.9) million from $(40.5) million in the prior year period. This improvement was primarily driven by substantial decreases in both research and development and general and administrative expenses, which were influenced by prior workforce reductions. However, collaboration revenue saw a notable decline, and the company's cash and marketable securities decreased compared to the end of 2025.

Alector, Inc. announced the discontinuation of its PROGRESS-AD Phase 2 clinical trial for nivisnebart (AL101/GSK4527226) in early Alzheimer's disease following an interim futility analysis. Concurrently, the company reported a net loss of $22.9 million for Q1 2026, an improvement from $40.5 million in Q1 2025. Alector's cash, cash equivalents, and investments totaled $206.5 million as of March 31, 2026, providing a runway at least through 2027. The company is now prioritizing its Alector Brain Carrier (ABC) platform and its pipeline of ABC-enabled programs for neurodegenerative diseases.

Alector, Inc. reported its first quarter 2026 financial results, with a net loss of $22.9 million, a significant reduction from the prior year. The company holds $206.5 million in cash, cash equivalents, and investments, projected to fund operations at least through 2027. While Alector continues to advance its Alector Brain Carrier (ABC) platform and related programs for neurodegenerative diseases, it announced the discontinuation of the global Phase 2 clinical trial for nivisnebart in early Alzheimer's disease following a futility analysis.

Alector, Inc. announced the discontinuation of its Phase 2 PROGRESS-AD trial for nivisnebart (AL101/GSK4527226) in individuals with early Alzheimer's disease. An independent data monitoring committee (IDMC) concluded that the trial was unlikely to meet its primary endpoint of slowing disease progression. Despite this setback, Alector remains focused on advancing its broader pipeline of novel ABC-enabled candidates, including an anti-Aβ antibody for AD targeting an IND submission in Q1 2027 and a GCase ERT for PD targeting an IND in 2027.

Alector, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on Wednesday, June 17, 2026, at 8:00 a.m. Pacific Time. Stockholders will vote on the election of three Class II directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm for 2026, and an advisory vote to approve named executive officer compensation. The Board of Directors recommends voting "FOR" all proposals. The record date for voting is April 20, 2026, with 111,025,187 shares outstanding.